Arena Investors’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Arena Investors’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-94,516	Closed	-$3.45K	–	88
2023 Q1	$3.45K	Hold	94,516	–	–	﹤0.01%	74
2022 Q4	$4.82K	Hold	94,516	–	–	﹤0.01%	79
2022 Q3	$3.72K	Hold	94,516	–	–	﹤0.01%	148
2022 Q2	$6K	Buy	+94,516	New	+$15.2K	﹤0.01%	155

Arena Investors's EUCRW Position: Q2 2023 in Review

Arena Investors sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2023, closing a stake of 94,516 shares — an estimated $3.45K sold.

Arena Investors first reported a position in EUCRW in Q2 2022 and held it in 4 quarters. The position peaked at $6K in Q2 2022. 0 funds tracked by Wall St. Rank hold EUCRW as of Q2 2023.

Arena Investors reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2023 after selling out during the quarter.
Arena Investors sold 94,516 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2023, an estimated $3.45K.
Arena Investors first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q2 2022 and held it in 4 quarters.
Arena Investors's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $6K in Q2 2022.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2023.

Based on Arena Investors's 13F filing for Q2 2023, filed 14 Aug 2023.